Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04486352 · ClinicalTrials.gov registry record · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
A Phase 1 study of Endometrial Cancer, sponsored by Alliance Foundation Trials.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
- 20
- Study locations
NCT04486352: Recruiting Phase 1 study of Endometrial Cancer, sponsored by Alliance Foundation Trials.
NCT04486352 is a Phase 1 study of Endometrial Cancer that is actively recruiting participants, run by Alliance Foundation Trials. The registered enrollment target is 148 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04486352, a Phase 1 study of Endometrial Cancer, is actively recruiting participants, sponsored by Alliance Foundation Trials.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Primary Outcome
AFT-50A Protocol: Overall response rate for each biomarker cohort is defined as the proportion of participants achieving a complete (CR) or partial (PR) response on two consecutive occasions at least 4 weeks apart, as determined by the investigator from AFT50A Protocol: Tumor assessments per RECIST v1.1.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Ipatasertib
- DRUG Talazoparib
- DRUG Atezolizumab - 28 Day Cycle
- DRUG Trastuzumab emtansine
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
New Jersey
- Englewood Health - Englewood
- Atlantic Health Systems/Morristown Medical Center - Morristown
New York
- Roswell Park - Buffalo
- Weill Cornell Medicine - New York
District of Columbia
- Medstar Georgetown Cancer Institute - Washington D.C.
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
Illinois
- University of Chicago - Chicago
Kansas
- University of Kansas Cancer Center - Westwood
Maine
- Maine Medical Center - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2021-10-20 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
What NCT04486352 shows while recruiting
NCT04486352 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT04486352 names 20 study sites across 17 states, led by California, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT04486352 about?
NCT04486352 is a clinical study titled "A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer". This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening ...
What is the current status of trial NCT04486352?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2021-10-20. Estimated completion is 2027-10.
What conditions does trial NCT04486352 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT04486352?
The interventions under investigation include: Bevacizumab (DRUG), Ipatasertib (DRUG), Talazoparib (DRUG), Atezolizumab - 28 Day Cycle (DRUG), Trastuzumab emtansine (DRUG).
Who is sponsoring clinical trial NCT04486352?
This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04486352 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04486352's enrollment target sits among peer trials
148 81st of 181 higher than 101 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04639297 · 148 participants · NA
NeuroVision vs Standard Neuromonitoring
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI